ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 宜明昂科生物醫藥技術（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1541） 自願公告 IMC-003/IMM72 第一期臨床試驗的首名患者給藥 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致之任何損失承擔任何責任。 – 2 – IMC-003/IMM72為通過基因改造的新一代啟動素受體IIA-Fc型(ActRIIA-Fc)融合 蛋白，具有更高的活性及品質。本集團擁有IMC-003/IMM72的全球知識產權以 及開發及商業化權利。 – 1 – 根據香港聯合交易所有限公司證券上市規則第18A.05條的警示聲明：本公司無 法保證能夠成功開發或最終上市銷售IMC-003/IMM72。本公司股東及潛在投資 者在買賣本公司股份時應謹慎行事。 承董事會命 宜明昂科生物醫藥技術（上海）股份有限公司 董事長兼執行董事 田文志 中國上海，二零二五年八月十八日 於本公告日 ...

Core Viewpoint - Yiming Anke-B (01541.HK) announced that it will hold a board meeting on August 26, 2025, to consider and approve the interim results for the six months ending June 30, 2025, and to discuss the potential declaration of an interim dividend, if any [1] Group 1 - The board meeting is scheduled for August 26, 2025 [1] - The meeting will focus on the interim performance results for the six months ending June 30, 2025 [1] - The company will also consider the proposal for an interim dividend distribution [1]

（於中華人民共和國註冊成立的股份有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致之任何損失承擔任何責任。 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. （股份代號：1541） 宜明昂科生物醫藥技術（上海）股份有限公司 董事會會議召開日期 宜明昂科生物醫藥技術（上海）股份有限公司（「本公司」）董事（「董事」）會（「董 事會」）謹此宣佈，本公司將於二零二五年八月二十六日（星期二）舉行董事會 會議，藉以（其中包括）考慮及批准本公司及其附屬公司截至二零二五年六月 三十日止六個月的中期業績及其刊發，並考慮建議派發中期股息（如有）。 承董事會命 宜明昂科生物醫藥技術（上海）股份有限公司 董事長兼執行董事 田文志 中國上海，二零二五年八月十二日 於本公告日期，董事會由以下成員組成：(i)執行董事田文志博士、李松先生、關梅女士及 張如亮先生；(ii)非執行董事徐聰博士及付大偉女士；及(iii)獨立非執行董事朱禎平博士、 Kendall ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 宜明昂科生物醫藥技術（上海）股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01541 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 396,277,305 | RMB | | 1 RMB | | 396,277,305 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 396,277,305 | RMB | | 1 RMB | | 396,277,305 | ...

Group 1 - The Hong Kong biotechnology stocks collectively rose, with notable increases in several companies' stock prices [1][2] - Beihai Kangcheng-B saw a rise of nearly 19%, while other companies like Gilead Sciences-B and Ascentage Pharma-B also experienced significant gains of over 15% and 9% respectively [1][2] - The overall trend indicates a positive sentiment in the biotechnology sector, with multiple companies achieving gains of over 5% [1][2] Group 2 - Specific stock performance includes: Beihai Kangcheng-B at 18.99% increase, Gilead Sciences-B at 15.30%, and Ascentage Pharma-B at 9.48% [2] - The market capitalization of these companies varies significantly, with Gilead Sciences-B at approximately 11.477 billion and Ascentage Pharma-B at about 29.86 billion [2] - Other notable performers include Jiahua Bio-B and Beikang Medical-B, both showing increases of over 7% [1][2]

宜明昂科-B(01541)发布公告，于IMM2510/AXN-2510获FDA批准于美国展开I期临床试验后，公司已从 Instil收取1000万美元的里程碑付款。截至本公告日期，根据授权及合作协议收取的付款总额已达3000 万美元(包括里程碑付款)，显示公司与Instil之间的持续进展及坚定承诺。 ...

Group 1 - The core point of the article is that Yiming Anke-B (01541) has received FDA approval to initiate Phase I clinical trials for IMM2510/AXN-2510 in the United States, leading to a milestone payment of 10 million USD from Instil [1] - As of the date of the announcement, the total payments received under the authorization and collaboration agreement have reached 30 million USD, including milestone payments, indicating ongoing progress and commitment between the company and Instil [1]

Core Viewpoint - The company has received FDA approval for its drug IMM2510/AXN-2510 to initiate Phase I clinical trials in the U.S., leading to a milestone payment of $10 million from Instil, reflecting ongoing progress and commitment in their partnership [1] Group 1 - The total payments received under the licensing and collaboration agreement with Instil have reached $30 million, including milestone payments [1] - IMM2510/AXN-2510 is a bispecific antibody targeting PD-L1 and VEGF, currently being developed for the treatment of various solid tumors [1] - The drug differentiates itself from other PD-(L)1xVEGF bispecific antibodies by blocking multiple VEGF receptor ligands beyond VEGF-A, utilizing PD-L1 as an anchor point in the tumor microenvironment, and enhancing antibody-dependent cellular cytotoxicity (ADCC) to directly kill PD-L1 positive tumor cells [1]

Core Viewpoint - The announcement highlights the ongoing collaboration between the company and Instil, with significant milestone payments received, indicating progress in the development of a dual-specificity antibody for cancer treatment [1] Group 1 - The company has received a milestone payment of 10 million USD from Instil since signing the licensing and collaboration agreement with AXION BIO on August 1, 2024 [1] - The total payments received under the agreement have reached 30 million USD as of the date of the announcement, reflecting a commitment to continued progress with Instil [1] - IMM2510/AXN-2510 is a dual-specificity antibody targeting PD-L1 and VEGF, currently being developed for the treatment of various solid tumors [1]

本公告由宜明昂科生物醫藥技術（上海）股份有限公司（「本公司」，連同其附屬 公司統稱「本集團」）自願作出，以告知本公司股東及潛在投資者有關本集團的 最新業務發展情況。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 宜明昂科生物醫藥技術（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1541） 自願公告 收到與AXION BIO的授權及 合作協議項下里程碑付款 茲提述本公司日期為2024年8月1日、2024年8月22日、2024年9月11日、2025年5 月7日及2025年7月2日的公告，內容有關（其中包括）(i)與Instil Bio, Inc.（「Instil」， NASDAQ：TIL)的全資附屬公司Axion Bio, Inc.（「Axion Bio」，前稱SynBioTx Inc.） 訂立日期為2024年8月1日的授權及合作協 ...